Glycolipid-Based Compound Α-Sulfoquinovosyl-Acylpropanediol Improves Radiation Response in Human Mesothelioma Xenografts Using Athymic Murine Systems
Keywords:
Mesothelioma, Glycolipid compounds, Tumor microenvironmentAbstract
Malignant mesothelioma represents a highly aggressive neoplasm with limited therapeutic responsiveness and poor prognosis despite multimodal treatment strategies. Radiotherapy remains a cornerstone in its management; however, intrinsic and acquired resistance significantly compromises treatment efficacy. This study investigates the potential of a glycolipid-derived compound, α-sulfoquinovosyl-acylpropanediol (SQAP), to enhance radiosensitivity in human mesothelioma xenograft models using athymic murine systems. The research is grounded in the hypothesis that modulation of tumor microenvironmental dynamics, particularly angiogenesis and hypoxia, can significantly improve radiation response.
The study integrates experimental and theoretical frameworks derived from prior investigations on tumor radiosensitizers, angiogenic regulation, and microenvironmental remodeling. SQAP is evaluated for its mechanistic role in altering hypoxia-inducible pathways, inhibiting angiogenesis, and modulating DNA repair processes. Using xenograft models, the compound’s influence on tumor growth delay, vascular normalization, and cellular apoptosis under radiation exposure is systematically analyzed.
Results indicate that SQAP significantly enhances radiation-induced cytotoxicity by facilitating oxygenation within tumor tissues and disrupting angiogenic signaling pathways. The compound demonstrates a dual mechanism involving both direct inhibition of tumor proliferation and indirect sensitization via microenvironmental modification. These findings align with existing literature emphasizing the importance of angiogenic switch regulation and hypoxia mitigation in improving radiotherapy outcomes (Hanahan and Folkman, 1996; Jain, 2005).
The study further evaluates translational implications, highlighting SQAP’s potential integration into clinical radiotherapy protocols. However, limitations related to preclinical model generalizability and long-term toxicity require further investigation. Overall, this research contributes to the evolving paradigm of radiosensitization through targeted molecular interventions, offering a promising avenue for improving therapeutic efficacy in resistant malignancies such as mesothelioma.
References
Anderson M, Storm HH. Cancer incidence among Danish thorotrast-exposed patients. J Natl Cancer Inst 1992;84:1318–25.
Binder A, Serafin A, Bohm L. Abrogation of G2/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Radiat Res 2000;154:640–9.
Bolukbas S, Manegold C, Eberlein M et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011;71:75–81.
Folkman J, Watson K, Ingber D et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–64.
Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
Hanashima S, Mizushina Y, Yamazaki T et al. Synthesis of sulfoqionovosylacylglycerols, inhibitors of Eukaryotic DNA Polymerase α and β. Bioorg Med Chem 2001;9:367–76.
Harrington KJ, Billingham LJ, Brunner TB et al. NCRI clinical and translational radiotherapy research working group, guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer 2011;23:628–39.
Horsman M, Bohm L, Margison G et al. Tumor radiosensitizers-current status of development of various approaches: report of an international atomic energy agency meeting. Int J Radiat Oncol Biol Phys 2006;64:551–61.
Hu Y, Liu J, Huang H. Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem 2013;114:498–509.
Iwamoto H, Nakamura T, Koga H et al. Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off " in a hepatoma mouse model. Mol Ther Oncolytics 2015;2:15020.
Izaguirre-Carbonell J, Kawakubo H, Murata H et al. Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity. Sci Rep 2015;5:15136.
Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.
Karar J, Maity A. Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 2009;8:1994–2001.
Kawakubo H, Kamisuki S, Suzuki K et al. SQAP, an acyl sulfoquinovosyl derivative, suppresses expression of histome deacetylase and induces cell death of cancer cells under hypoxic conditions. Bioscience, Biotechnology, and Biochemistry 2021;85:85–91.
Kutara K, Mochizuki Y, Ohnishi A et al. The outcome and CT findings of low-dose intensity modulated radiation therapy with SQAP in a cat with thymoma. Vet Sci 2020;7:203.
Marinaccio A, Binazzi A, Cauzillo G et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 2007;43:2722–8.
Mizushina Y, Watanabe I, Ohta K. Studies on inhibitors of mammalian DNA polymerase α and β: sulfolipids from a pteridophyte, Athyrium niponicum. Biochem Pharmacol 1998;55:537–41.
Morodomi Y, Yano T, Kinoh H et al. Bioknife, a uPA activity-dependent oncolytic sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression. Mol Ther 2012;20:769–77.
Mori Y, Sahara H, Matsumoto K et al. Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′-sulfoquinovosyl-1′-monoacylglycerol, targeting angiogenesis. Cancer Sci 2008;99:1063–70.
Murayama T, Takahashi K, Natori Y et al. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006;49:1–7.
Mutti L, Peikert T, Robinson B et al. Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol 2018;13:1269–83.
Ohta K, Hanashima S, Mizushina Y et al. Studies on a novel DNA polymerase inhibitor group, synthetic sulfoquinovosylacylglycerols: inhibitory action on cell proliferation. Mutat Res 2000;467:139–52.
Ohta K, Mizushina Y, Hirata N. Sulfoquinovosyldiacylglycerol, KM043, a new potent inhibitor of eukaryotic DNA polymerases and HIV-reverse transcriptase type 1 from a marine red alga, Gigartina tenella. Chem Pharm Bull 1998;46:684–6.
Ohta K, Mori Y, Ishima M et al. Remodeling of the tumor microenvironment by combined treatment with a novel radiosensitizer, {alpha}-sulfoquinovosylmonoacylglycerol ({alpha}-SQMG) and X-irradiation. Anticancer Res 2010;30:4397–404.
Sahara HIM, Takahashi N. In vivo anti-tumor effect of 3′-sulphonoquinovosyl 1′-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. Br J Cancer 1996;75:324–32.
Sahara H, Hanashima S, Yamazaki T et al. Anti-tumor effect of chemically synthesized sulfolipids based on sea urchin’s natural sulfoquinovosylmonoacylglycerols. Jpn J Cancer Res 2002;93:85–92.
Sakimoto I, Ohta K, Yamazaki T et al. Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. Cancer Res 2006;66:2287–95.
Sawada Y, Omoto K, Kohei N et al. Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer. Int J Urol 2015;22:590–5.
Sugarbaker D, Jaklitsch MT, Richards WG et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1998;117:54–65.
Takakusagi Y, Naz S, Takakusagi K et al. A multimodal molecular imaging study evaluates pharmacological alteration of the tumor microenvironment to improve radiation response. Cancer Res 2018;78:6828–37.
Tian J, Chen J, Ge C et al. Synthesis of PEGylated ferrocene nanoconjugates as the radiosensitizer of cancer cells. Bioconjug Chem 2016;27:1518–24.
Van T, Hanibuchi M, Kakiuchi S et al. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol 2011;68:497–504.
Verma V. Relationship and interaction of curcumin with radiation therapy. W J Clin Oncol 2016;10:275–83.
Weichert W, Roske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604–10.
Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008b;9:139–48.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Dr. Dmitry A. Volkov
This work is licensed under a Creative Commons Attribution 4.0 International License.
Individual articles are published Open Access under the Creative Commons Licence: CC-BY 4.0.
